Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

NCT00303797 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Refractory Chronic Lymphocytic Leukemia
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Stage IV Chronic Lymphocytic Leukemia
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
DRUG: sorafenib tosylate

Sponsor

National Cancer Institute (NCI)